| Previous Close | 75.86 |
| Open | 75.89 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 74.68 - 76.00 |
| 52 Week Range | 65.47 - 99.14 |
| Volume | 1,579,425 |
| Avg. Volume | 1,844,510 |
| Market Cap | 10.71B |
| Beta | 0.64 |
| PE Ratio (TTM) | -3.14 |
| EPS (TTM) | -23.8 |
| Earnings Date | Aug 8, 2017 - Aug 14, 2017 |
| Dividend & Yield | 0.64 (0.85%) |
| Ex-Dividend Date | 2017-05-24 |
| 1y Target Est | 75.87 |
- The Wall Street Journal•5 days ago
Health-Care Stocks Get a Boost From Senate Bill Rollout
Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.
- PR Newswire•6 days ago
Perrigo Company Retains Spencer Stuart for CEO Search
DUBLIN , June 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products ® ", today announced that the Company's Board ...
- PR Newswire•6 days ago
Perrigo Announces the Launch of Generic Equivalents to Derma-Smoothe/FS® Scalp Oil and Body Oil
TASE: PRGO) today announced it has launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body Oil (fluocinolone acetonide topical oil, 0.01%). Derma-Smoothe/FS® Scalp Oil (fluocinolone acetonide scalp oil, 0.01%) and Derma-Smoothe/FS® Body Oil (fluocinolone acetonide topical oil, 0.01%) are indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to four weeks. Perrigo CEO John T. Hendrickson stated, "This launch is another example of Perrigo's ability to develop and bring to market important extended topical treatments.